Projects per year
Abstract
Perspective: Healthcare system.
Setting: Australian primary care.
Methods: A Markov model was used to synthesise data from a variety of sources. The model included all Australian women aged 15–49 years (N = 5,644,701). The time horizon was 35 years. Contraceptive use before reclassification was estimated using data from the Household, Income and Labour Dynamics in Australia (HILDA) survey, while survey data informed use after reclassification. Health outcomes included pregnancies, pregnancy outcomes (live birth, miscarriage, stillbirth, ectopic pregnancy and abortion), sexually transmitted infections, adverse events (venous thromboembolism, depression, myocardial infarction and stroke), ovarian cancer cases and quality-adjusted life-years. Costs included those related to general practitioner and specialist consultations, contraceptives and other medicines, pharmacist time, hospitalisations and adverse events. All costs were reported in 2016 Australian Dollars. A 5% discount rate was applied to health outcomes and costs.
Results: Reclassifying OCPs resulted in 85.70 million quality-adjusted life-years experienced and costs of $46,910.14 million over 35 years, vs. 85.68 million quality-adjusted life-years experienced and costs of $50,274.95 million with OCPs remaining prescription-only. Thus, reclassifying OCPs was more effective and cost saving. However, a sensitivity analysis found that more research on the probability of pregnancy in women not using contraception and not trying to conceive is needed.
Conclusion: Reclassifying OCPs is likely to be considered cost effective by Australian decision makers.
Original language | English |
---|---|
Pages (from-to) | 1049-1064 |
Number of pages | 16 |
Journal | PharmacoEconomics |
Volume | 37 |
Issue number | 8 |
Early online date | 9 May 2019 |
DOIs | |
Publication status | Published - 1 Aug 2019 |
Fingerprint Dive into the research topics of 'Is reclassification of the oral contraceptive pill from prescription to pharmacist-only cost effective? Application of an economic evaluation approach to regulatory decisions'. Together they form a unique fingerprint.
Projects
- 1 Finished
-
Proposed research project for the WSMI general assembly in 2017
Parkinson, B., Cutler, H. & Schroeder, L.
11/03/16 → 31/12/16
Project: Research
Press / Media
-
Over-the-counter contraceptive pill could save the health system $96 million a year
Bonny Parkinson & Mutsa Gumbie
31/05/19 → 1/06/19
2 Media contributions
Press/Media: Expert Comment
-
Is reclassification of the oral contraceptive pill from prescription to pharmacist-only cost effective? Application of an economic evaluation approach to regulatory decisions
Bonny Parkinson, Mutsa Gumbie, Henry Cutler, Natalie Gauld & Virginia Mumford
23/05/19 → 31/05/19
4 items of Media coverage, 1 Media contribution
Press/Media: Research
-
Pharmacists say doctors blocking scheduling reform
20/10/17
1 item of Media coverage
Press/Media: Expert Comment
Activities
- 3 Presentation
-
Is reclassifying the oral contraceptive pill to over-the-counter cost-effective?
Henry Cutler (Speaker)2018Activity: Talk or presentation › Presentation
-
An economic evaluation framework to inform the scheduling of medicines in Australia
Bonny Parkinson (Speaker)30 May 2018 → 1 Jun 2018Activity: Talk or presentation › Presentation
-
An economic framework to inform the scheduling of drugs
Bonny Parkinson (Speaker)17 Oct 2017 → 19 Oct 2017Activity: Talk or presentation › Presentation
Impacts
-
Enhancing medicine scheduling decisions through economics
Bonny Parkinson (Participant), Henry Cutler (Participant), Mutsa Gumbie (Participant), Natalie Gauld (Participant), Virginia Mumford (Participant), Philip Haywood (Participant)
Impact: Policy impacts, Economy impacts, Quality of life impacts